Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors

American Journal of Hematology

Volumn 87, Issue 11, 2012, Pages

  Redaelli, Sara ^a   Mologni, Luca ^a   Rostagno, Roberta ^a   Piazza, Rocco ^a   Magistroni, Vera ^a   Ceccon, Monica ^a   Viltadi, Michela ^a   Flynn, Daniel ^b   Gambacorti Passerini, Carlo ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b Deciphera Pharmaceuticals LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; MUTANT PROTEIN; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REBASTINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; DRUG BIOAVAILABILITY; ENZYME INHIBITION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; IC 50; LETTER; MOUSE; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SEQUENCE ANALYSIS, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84867904395     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23338     Document Type: Letter

References (20)

1. Kantarjian H, Shah N, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med, in press.
2. Saglio G, Kim D, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Eng J Med, in press.
3. Puttini M, Coluccia AML, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314-11322.
4. Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicus L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J Clin Oncol 2012.
5. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.
6. Cortes J, Talpaz M, Bixby D, et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: Emerging safety and clinical response findings. ASH Annual Meeting Abstracts 2010;116: 210.
7. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75-85.
8. Apperley J. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-1029.
9. Zhou T, Commodore L, Huang W, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011; 77: 1-11.
10. Chan Wayne W, Wise Scott C, Kaufman Michael D, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011; 19: 556-568.
11. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27: 469-471.
12. Jabbour E, Jones D, Kantarjian H, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009; 114: 2037.
13. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 2006; 108: 2332-2338.
14. O'Hare T, Eide CA, Tyner JW, et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA 2008; 105: 5507-5512.
15. Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641-1650.
16. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9: 625-632.
17. Mologni L, Dekhil H, Ceccon M, et al. Colorectal tumors are effectively eradicated by combined inhibition of beta-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res 2010; 70: 7253.
18. Piazza RG, Magistroni V, Gasser M, et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia 2005; 19: 132-134.
19. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 1996; 98: 521-528.
20. Le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst